Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Poldine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 12/20 | 0.48 |
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 12/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bevonium SCHEMBL25016 | 0.97 | CHRM2 (0.45) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| Poldine SCHEMBL1641786 | 0.92 | CHRM2 (0.55) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| Bevonium SCHEMBL28439272 | 0.91 | CHRM2 (0.46) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| Bevonium SCHEMBL1650540 | 0.89 | CHRM2 (0.51) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| Bevonium SCHEMBL28086190 | 0.83 | CHRM2 (0.47) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| Oxypyrronium SCHEMBL29388831 | 0.78 | POLB (0.57) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| Oxypyrronium SCHEMBL916858 | 0.77 | CHRM2 (0.56) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| Poldine SCHEMBL28086707 | 0.76 | CHRM2 (0.67) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| SCHEMBL1087914 | 0.74 | CHRM2 (0.47) | CHRM2CHRM3CYP2D6KCNH2LMNA | |
| SCHEMBL1087913 | 0.74 | CHRM2 (0.47) | CHRM2CHRM3CYP2D6KCNH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118795664-B | Visible light, short wave infrared dual-band common-caliber integrated optical system | 长春通视光电技术股份有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-118795664-A | Visible light, short wave infrared dual-band common-caliber integrated optical system | 长春通视光电技术股份有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-116540407-B | Design method, system, equipment and medium for low polarization aberration three-reflection optical system | 中国科学院长春光学精密机械与物理研究所 | 2023-09-22 | — | — | CN | claimed |
| CN-116540407-A | Design method, system, equipment and medium for low polarization aberration three-reflection optical system | 中国科学院长春光学精密机械与物理研究所 | 2023-08-04 | — | — | CN | claimed |
| CN-115303328-A | Track monitoring system based on COTDR | 天津光电集团有限公司 | 2022-11-08 | — | — | CN | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0212875-A2 | Medicinal composition and method of making same | Tucker, William Gough (US) | 1987-03-04 | — | — | EP | disclosed |
| EP-0198034-A1 | PHYSIOLOGICAL MEANS OF ENHANCING TRANSDERMAL DELIVERY OF DRUGS. | KEY PHARMA (US) | 1986-10-22 | — | — | EP | disclosed |
| WO-1986002272-A1 | PHYSIOLOGICAL MEANS OF ENHANCING TRANSDERMAL DELIVERY OF DRUGS | KEY PHARMACEUTICALS, INC. (US) | 1986-04-24 | — | — | WO | disclosed |
| US-4207890-A | Drug-dispensing device and method | MCNEILAB, INC. (US) | 1980-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | CHRM3 857/4885CHRM1 1103/4885CHRM2 1115/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | CHRM3 560/4885CHRM1 312/4885CHRM2 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.